NCT Number: NCT00242229
Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.
Looking for future studies?
Notify MeKey information
Conditions
Age range
65 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Outpatients men and women aged 65 years or older.
- Mini Mental State Examination score of 24 or above.
- Subjects must have a primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), single or recurrent episode, without psychotic features, on study day 1, if depressive symptoms for at least 30 days prior to screening visit and minimum screening and study day -1 (baseline) scores of 16 on the Hamilton Psychiatric Rating Scale for Depression (HAM-D17).
Exclusion criteria
- Significant risk of suicide based on clinical judgment, including common suicidal thoughts, and suicide being considered as a possible solution, even without specific plans or intention.
- Current (within 12 months of baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder as assessed by the modified Mini International Neuropsychiatric Interview (MINI). Current (within 12 months of baseline) generalized anxiety disorder, panic disorder, or social anxiety disorder as assessed by the modified MINI and considered by the investigator to be primary, causing a higher degree of distress or impairment than MDD. Presence (within 12 months of baseline) of a clinically important personality disorder (such as antisocial, schizotypal, histrionic, borderline, narcissistic). Presence of dementia.
- Depression associated with the presence of an organic mental disorder due to a general medical condition or a neurologic disorder.
Other exclusion applies.
Treatment and study plan
Primary outcomes
-
To evaluate the long-term safety and tolerability of DVS SR in elderly outpatients with MDD.
Secondary outcomes
-
To evaluate the long-term response of subjects receiving DVS SR for the clinical global evaluation, functionality, general well-being, pain and absence of depressive symptoms (Hamilton Psychiatric Rating Scale for Depression 17-item score < or = 7).
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A 6 Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder (MDD)
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Oct 19, 2005
- Registry last updated
- Aug 19, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders
NCT03898297
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsStudy Evaluating Safety and Efficacy of Ropanicant in MDD Patients
NCT06126497
Behavior, Behavioral Symptoms
Bellflower, California, United States
View Trial DetailsCBT+ for Depression
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsTrial of Mirtazapine for Depression in IBD
NCT06309472
Behavior, Behavioral Symptoms
London, United Kingdom
View Trial Details